Abstract
Alzheimer’s disease (AD) is the most important cause of dementia and a
complex chronic neurodegenerative disease. Many of the currently marketed drugs are
used to treat this disease condition, but a major issue with these drugs is their
neurotoxicity. Alzheimer's treatment with the FDA approval of memantine resolves the
neurotoxicity issue. Memantine acts on glutamate and its receptors in the treatment of
AD. Recent studies show that NMDA receptor-acting drugs are doing well in the
healing of Alzheimer's patients, because of their selectivity on receptor and
neuroprotective activity. The present work is an attempt to collect updated information
about memantine and glutamate antagonists used for the treatment of AD.